Anti-leishmanial Activity of Amphotericin B Entrapped in Cationic Liposomal Formulation

• Single shot application of cationic liposome entrapped AmB can induce successful clearance of infection with induction of immune activation of host.
• This formulation has very good antileishmanial activity, so there is a good possibility for its commercialization.
• It can prevent PKDL development.

The project has already started to produce GLP level liposomal formulations for commercialization standards. The co-development project with industry will be completed in July 2021.

• After this co-development R&D activity CSIR-IICB will be the stake holder for commercialization agreement with the industry.

• Single shot application of liposomes
• Synergistic effect of immune activating cationic liposome
• Remarkable low dose of AmB can be obtained that can induce Th1 response in host.